Treatment | Clinical score | Antibody response | Body temperature | Serum amyloid A | WBC | Pneumonia | Pleuritis | Thoracic adhesions | Mean |
|---|
ETH20-1 × 3 | 7 | 6 | 8 | – | – | – | – | – | 7.6 |
ETH20-2 × 3 | 5 | - | 4 | – | 4 | 6 | 4 | 4 | 5.4 |
ETH30-1 × 3 | 8 | 5 | 2 | – | – | 7 | 7 | – | 6.6 |
ETH30-2 × 5 | 1 | 3 | 4 | 1 | 2 | 3 | 2 | 5 | 2.6 |
UPA30-1 × 3 | 6 | - | 3 | – | 3 | 5 | 6 | 3 | 5.3 |
UPA30-1 × 5 | 4 | 1 | 6 | – | 1 | 4 | 5 | 6 | 4.4 |
UPA60 + UPA30-1 × 2 | 2 | 4 | 1 | 2 | 6 | 1 | 3 | 1 | 2.5 |
ETH30 + UPA30-1 × 3 | 2 | 2 | 6 | – | 5 | 2 | 1 | 2 | 3.4 |
- The numbers in the table indicate the rank of the treatment effect as measured by the generalized estimating equation (GEE) with adjustment for the experiment effect and repeated measures within pig. A hyphen indicates that the treatment effect was not significantly different than the untreated group and therefore was not ranked. The treatment group nomenclature is: the medicinal product, either procaine benzylpenicillin in a water suspension (ETH) or procaine benzylpenicillin in an oil suspension (UPA); dose in mg/kg (20, 30 or 60 mg/kg); dose frequency (once or twice daily) and treatment duration in days (3 or 5 days). For example, ETH20-2 × 3 should read as: procaine benzylpenicillin in a water suspension 20 mg/kg bodyweight twice daily for three days. The last column is the mean ranking for each treatment group which gives an indication of the total ranking of the treatment across clinical outcomes. The mean was calculated by assigning a value of 8 to each non-significant (–) response indicating that it was equivalent to being ranked lowest
